×
About 1,955 results

ALLMedicine™ Gallbladder Cancer Center

Research & Reviews  727 results

Identification of the prognostic value of elevated ANGPTL4 expression in gallbladder ca...
https://doi.org/10.1002/cam4.4150
Cancer Medicine; Wang FT, Li XP et. al.

Aug 1st, 2021 - Cancer-associated fibroblasts (CAFs) with different gene profiles from normal fibroblasts (NFs) have been implicated in tumor progression. Angiopoietin-like protein 4 (ANGPTL4) has been shown to regulate tumor angiogenesis and metastasis, and pred...

Genetic Susceptibility of DCC Gene in Gallbladder Cancer in Kashmir and Meta-Analysis.
https://doi.org/10.1080/01635581.2021.1949728
Nutrition and Cancer; Malik MA, Malik SA et. al.

Jul 15th, 2021 - Deleted in colorectal carcinoma (DCC) A > G (rs714) is the most widely studied SNP of tumor suppressor DCC gene found to be associated with increased risk of various cancers. Therefore, the aim of present case control study was to investigate the ...

Complete remission in metastatic primary malignant melanoma of the esophagus with nivol...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278729
Journal of Medical Case Reports; Okamoto T, Nakano E et. al.

Jul 15th, 2021 - Primary malignant melanoma of the esophagus is a rare form of mucosal melanoma with a poor prognosis. While immune checkpoint inhibitors have recently extended overall survival in metastatic melanoma, data on their effects on primary malignant mel...

Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241731
International Journal of Biological Sciences; Bian R, Dang W et. al.

Jul 10th, 2021 - Rac GTPase activating protein 1 (RACGAP1) has been characterized in the pathogenesis and progression of several malignancies, however, little is known regarding its role in the development of gallbladder cancer (GBC). This investigation seeks to d...

Elevation of CA 19-9 in Mirizzi Syndrome in the Absence of Malignancy: A Case Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255084
The American Journal of Case Reports; Moshref LH, Mandili RA et. al.

Jul 2nd, 2021 - BACKGROUND Mirizzi syndrome (MS) is relatively a rare condition; incidence rates may increment with age. It is characterized as an obstruction of the common hepatic duct (CHD) auxiliary to outward compression of an infected stone in the cystic duc...

see more →

Guidelines  3 results

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Gallbladder cancer: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527853
HPB : the Official Journal of the International Hepato Pa... Aloia TA, Járufe N et. al.

Jul 15th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallbladder carcinoma in order to establish practice guidelin...

Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Midd...
https://doi.org/10.6004/jnccn.2010.0123
Journal of the National Comprehensive Cancer Network : JN... Yusuf MA, Kapoor VK et. al.

May 11th, 2011 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers address hepatocellular cancer, cancer of the gallbladder, extrahepatic cholangiocarcinoma, and intrahepatic cholangiocarcinoma. Hepatocellular cancer inci...

see more →

Clinicaltrials.gov  29 results

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
https://clinicaltrials.gov/ct2/show/NCT03201458

Feb 5th, 2020 - PRIMARY OBJECTIVES: I. To assess the progression free survival (PFS) of patients receiving atezolizumab monotherapy and cobimetinib in combination with atezolizumab for unresectable cholangiocarcinoma. SECONDARY OBJECTIVES: I. To assess the overal...

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT00478140

Aug 20th, 2019 - PRIMARY OBJECTIVE: I. Determine the objective response rate and duration of objective response in patients with HER2/neu-positive advanced gallbladder or biliary tract cancer treated with trastuzumab (Herceptin). SECONDARY OBJECTIVES: I. Assess th...

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT02520141

May 17th, 2019 - PRIMARY OBJECTIVES: I. Determine the progression-free survival (PFS) of ramucirumab in advanced biliary cancers (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer) who have received prior chemotherapy. SECOND...

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
https://clinicaltrials.gov/ct2/show/NCT03257761

May 3rd, 2019 - PRIMARY OBJECTIVES: I. To evaluate the dose limiting toxicities and determine the maximum tolerated dose/recommended phase 2 dose of the combination of guadecitabine and durvalumab. (Dose escalation part) II. To evaluate the objective response rat...

Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer
https://clinicaltrials.gov/ct2/show/NCT03358849

Jan 16th, 2019 - Cholangiocarcinoma refers to bile duct cancer (bile duct cancer) and gallbladder cancer that develop in the gallbladder. According to the data from National Cancer Information Center in 2013, the incidence of cancer in Korea is 5,283, which corres...

see more →

News  18 results

Advanced Glycation Endproducts and Liver Cancer: Findings Unexpected, Show Inverse Relationship
https://www.medscape.com/viewarticle/951914

May 26th, 2021 - Contrary to expectations, high dietary intake of advanced glycation endproducts (AGEs), including those from foods that are deep fried, grilled, or broiled, was associated with a lower risk of hepatocellular carcinoma (HCC) in a large, multination...

AGA CPU: Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/gihepnews/article/209796/hepatology/aga-cpu-surveillance-hepatobiliary-cancers-primary-sclerosing?channel=346
Bianca Nogrady, MDedge News

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical update published in Clinical G.

AGA Clinical Practice Update: Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/gihepnews/article/209796/hepatology/aga-clinical-practice-update-surveillance-hepatobiliary-cancers?channel=346
Bianca Nogrady, MDedge News

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical practice update published in C.

Surveillance for hepatobiliary cancers in primary sclerosing cholangitis
https://www.mdedge.com/internalmedicine/article/209796/hepatology/surveillance-hepatobiliary-cancers-primary-sclerosing?channel=75
Bianca Nogrady

Oct 9th, 2019 - All adult patients with primary sclerosing cholangitis should be screened at least annually for cholangiocarcinoma and gallbladder cancer, particularly in the first year after their diagnosis, according to a clinical update published in Clinical G.

GAP Regimen Tops Historical Data for Advanced Biliary Tract Ca
https://www.medpagetoday.com/hematologyoncology/othercancers/79313

Apr 18th, 2019 - The addition of nab-paclitaxel to standard-of-care gemcitabine-cisplatin -- known as the GAP regimen -- prolonged survival for patients with advanced biliary tract cancers compared with historical controls of gemcitabine-cisplatin alone, according...

see more →

Patient Education  5 results see all →